公开(公告)号：US11732266B2

公开(公告)日：2023-08-22

申请号：US17080771

申请日：2020-10-26

Applicant: AMGEN INC.

Inventor： Michael Ollmann ,  Yang Li ,  Jun Zhang ,  Oliver Homann ,  Leslie P. Miranda ,  Justin K. Murray ,  Bin Wu ,  Oh Kyu Yoon ,  John Gordon Allen ,  Chawita Netirojjanakul ,  Yuan Cheng

IPC: C12N15/113 ,  A61P9/10 ,  A61P3/06 ,  C07K16/28

CPC classification number: C12N15/1138 ,  A61P3/06 ,  A61P9/10 ,  C07K16/2851 ,  C07K2317/526 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/317 ,  C12N2310/321 ,  C12N2310/332 ,  C12N2310/351 ,  C12N2310/3513 ,  C12N2310/321 ,  C12N2310/3521 ,  C12N2310/322 ,  C12N2310/3533 ,  C12N2310/322 ,  C12N2310/3531

Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.